McKesson Ventures highlights investment priorities amidst a trail of successful exits
McKesson Ventures is one of the most active investors in the biopharma software sector with Komodo Health, Evidation and M2Gen among its portfolio companies.
McKesson Ventures is one of the most active investors in the biopharma software sector with Komodo Health, Evidation and M2Gen among its portfolio companies.
M2Gen, which has been around since 2006, and Moffitt are part of the Oncology Research Information Exchange Network alliance, which has 17 cancer center members that have access to a data warehouse linking clinical and molecular data.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.